ypradat (@ypradat) profile picture

Postdoctoral researcher. Translational Research, Applied Mathematics, Computational Biology, Oncology. @GustaveRoussy @PrismCenter @FondationARC

Paris
Joined November 2019
Photo by ypradat (@ypradat)Photo by ypradat (@ypradat)
Just left #MAP2024 with inspiring talks x current hot topics in oncology! I was very pleased to cross path again with @PapaemmanuilLab and to attend with colleagues S. Dogan, @FAndreMD, @Elsa2Bernard from @GustaveRoussy. Many thanks to @FondationARC for the travel grant.
4
88
I am thrilled to announce that I will be supported by a postdoctoral fellowship from @FondationARC for the next 3y to investigate the molecular features of treatment-related myeloid leukemias. Work under the supervision of @Elsa2Bernard at @GustaveRoussy and part of @PrismCenter.
3
1
3
20
6,238
1st award @myESMO : I Ray-Coquard on rare gyne cancers. How to improve outcome: precise dg (referral), quality of network (infrastructure & scient collab), guidelines adh, inclusion of all stakeholders, database, biomarker driven approvals. @PrismCenter cited ! #ESMO2023
1
8
1
40
3,621
The DAISY trial of T-DXd in MBC with variable HER2 expression is out on @NatureMedicine. Many important findings, including a similar ORR with T-DXd in HER2-low (37.5%) & HER2-0 (29.7%) MBC. Congrats to @FerMosele @FAndreMD et al for this impressive work! nature.com/articles/s41591-0…
7
84
11
250
54,586
Very proud to see our work on the pan-cancer comparison of the genomic landscapes of primary and metastatic tumor published in this weeks issue of Nature: nature.com/articles/s41586-0…. @fran_mj88 @arne_van_hoeck @HartwigMedical @UMCU_CMM @oncodeinstitute @VHIO
1
49
2
142
19,103
.@PrismCenter selected to receive 30-40 M euros to build a Precision Oncology Center. Vision: to classify pts based on biology. Scientific strategy: bottom-up approach to model cancer biology in each pt (fig 2) for early cancer or relapse detection, & tt optimisation (fig 3).
12
38
2
140
20,236
ypradat retweeted
We financially and technically supported a pan-TCGA WES analysis in the @CD_AACR paper "Integrative #Pancancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer" by @ypradat, @DGautheret, @snikolae et al. aacrjournals.org/cancerdisco… @PrismCenter @GustaveRoussy
2
2
4
1,068
#Statistics thought of the day: futility of much high-dimensional omics research (false discovery rates be damned): when N<p there is often no correlation between estimated and actual effects hbiostat.org/bbr/hdata.html#…
5
25
5
120
31,604
Integrative #Pancancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer, by @ypradat, @DGautheret, @snikolae et al. https://nitter.gq/t.co/RY82diTwCn @PrismCenter @GustaveRoussy @centralesupelec @ParisSaclay @Inserm
10
1
21
3,869
Now online in @CD_AACR: Integrative Pan-cancer Genomic and Transcriptomic Analyses of Refractory #Metastatic Cancer - by @ypradat @DGautheret Sergey Nikolaev and colleagues @PrismCenter @GustaveRoussy @centralesupelec @ParisSaclay @Inserm aacrjournals.org/cancerdisco…
1
7
1
40
7,406
📯 Hear ye! Hear ye! The #TopTweet is presented to thee! 🥂 Congratulations to the team with Drs. Yanis Tazi (@taziyanis) and Ellie Papaemmanuil (@PapaemmanuilLab) from @MSKCancerCenter on the development of an open-access clinical decision support tool! nitter.gq/Hema_News/status/15582…
Yanis Tazi (@TaziYanis), Dr. Elli Papaemmanuil (@PapaemmanuilLab), and colleagues used comprehensive molecular profiling data from 3,653 patients to characterize and validate 16 molecular classes describing 100% of #AML patients. @MSKCancerCenter 📌 go.nature.com/3dmk3Z1
2
5
2,055
👉META-PRISM: 1,031 pan-cancer refractory metastatic tumors profiled via whole-exome and transcriptome sequencing. medrxiv.org/content/10.1101/…
39
2
122
Tks anirban ! RNA seq and whole exome in 1000 and 500 pretreated metastatic cancers. Interesting to see the impact of prior therapies, especially platinum, on DNA + discovery of new alterations involved in resistance (PTEN transloc). A huge work from PRISM (maybe futur center🤞)
Preprint from @ypradat @FAndreMD et al @PrismCenter @GustaveRoussy: Integrative pan-cancer genomic and transcriptomic analyses of refractory metastatic cancer medrxiv.org/content/10.1101/… Whole exome & transcriptome sequencing on >1,000 metastatic tumors including #PancreaticCancer
14
36
WES & RNAseq landscape of > 1,000 multi-resistant tumors treated @GustaveRoussy highlights the current gap in understanding treatment resistances. Preprint medrxiv.org/cgi/content/shor…. Data will be made available upon release in peer-reviewed journal. @centralesupelec @PrismCenter.
6
3
19
4 yrs ago, we discussed with Mathematicians ⁦@centralesupelec⁩ about integrating Maths in Cancer Research projects⁩. It’s nice to see papers coming on Mathematical models of cancer from our teams. Here a modeling of myeloproliferative disorders 👇 pnas.org/doi/10.1073/pnas.21…
8
1
52
Proud to have been part of this fantastic study and of Papaemmanuil's team! This work contributes to improving our understanding of highly-aggressive AML tumors and hopefully will help medical doctors better assess the risk profile of each patient.
Unified classification & risk stratification in AML. Trained & validated in 3,653 patients by @TaziYanis now published at: go.nature.com/3A6OXNS. Insights from this study adopted in ELN & WHO 2022. Data & Code Github:https://nitter.gq/t.co/UODSVHJUSY Webtool: aml-risk-model.com/
3
Very pleased and honored to have had the opportunity to present the first results of our study on META-PRISM, a cohort of > 1,000 very aggressive metastatic tumors. Thanks to @GustaveRoussy, @PrismCenter & @centralesupelec for making this possible. #ESHG2022
3
2
14